Independent. No tobacco money. No corporate fluff.THU, OCT 8

PouchDaily

The daily pulse of the nicotine pouch market

Regulation
US

What FDA's modified-risk order for ZYN actually allows — and what it doesn't

In June 2026, FDA let 20 ZYN pouches carry a reduced-risk claim versus cigarettes — the first ever for nicotine pouches. Here's what the order covers, what it requires, and why it's a precedent.

PouchDaily Desk·
FDAZYNMRTPPMIUnited Statesregulation

On June 30, 2026, the U.S. FDA issued modified risk tobacco product (MRTP) orders for 20 ZYN nicotine pouch products — the first time any nicotine pouch has been allowed to carry a reduced-risk claim versus cigarettes. This explainer breaks down what that order actually does, because the marketing labels rolling out on ZYN cans are a direct consequence of it.

What the claim says

The authorized claim is exact, and Swedish Match (owned by Philip Morris International) can only use it verbatim on the 20 covered products: "Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis."

Note what it does not say: it is a comparison to cigarettes, not a statement that ZYN is safe or risk-free. FDA's own language makes clear there is no safe tobacco or nicotine product, and the healthiest option is to quit entirely.

Which products are covered

The orders apply to specific products, not the whole category. The 20 variants are 10 flavors, each in 3 mg and 6 mg:

  • Cool Mint, Peppermint, Spearmint, Wintergreen, Menthol
  • Citrus, Coffee, Cinnamon, Smooth, Chill

The same products had already been authorized for sale through the regular PMTA process on January 16, 2025, when ZYN became the first nicotine pouch authorized by FDA. The MRTP orders are a second, separate layer: permission to market with a risk-comparison claim.

What the order demands in return

The authorization is not a free pass. It carries conditions:

  • Swedish Match must run postmarket surveillance and studies, including assessments of how consumers actually use the products and whether they understand the risk information.
  • The orders expire in five years, and renewal requires a new review.
  • FDA can modify or withdraw the orders if continued marketing no longer benefits public health — including if use by people who would not otherwise use nicotine increases.

Why it matters

This is a regulatory precedent, not just a ZYN marketing win. Modified risk orders have previously gone to snus products and heated tobacco — this is the first for pouches, the fastest-growing nicotine category in several markets. For manufacturers, it shows FDA will accept comparative risk evidence for pouches when the science supports it. For regulators elsewhere — including European countries weighing pouch restrictions or bans — it is a reference point for a risk-based approach instead of prohibition.

The claim itself is also a real competitive weapon in the U.S. market: it's the kind of statement no unauthorized competitor can legally make.

What to watch

  • Whether FDA's review of new pouch applications (including higher-strength and moist formats) follows the same risk-based logic.
  • Whether the five-year surveillance conditions surface real-world usage data that shapes the next round of orders.
  • How the claim appears on packaging and advertising, and whether public-health groups challenge the marketing in court or in comments to FDA.

Comparing ZYN flavors, strengths and prices across retailers? PouchFinder lists what is in stock where.

Event date: June 30, 2026. This is an explainer, not breaking news — the decision summary documents were posted by FDA in July 2026.

SOURCES: